Priority Review was monumental in so many ways....
1. It allows Amarin to beef up it's API sully chain.... as HD informed us... BASF was a supplier in 2012 bur in 2013 when FDA pulled the plug on Amarin's Anchor indication they cancelled contract and went to Teva ( Lavaza ) in US and Pronova for the European market.... BASF was 1 of4 at the time.... JT said it was a mutual split at the time and we could initiate under better conditions in the future... POSITIVE
2. Having SEPT. 2019 approval will make immense strides in tier pricing for 2020.... a Standard Approval would have us looking for changes in later 2020.... insurance coverage means everything... think about Medicare coverage in early 2020 as well as corporate (business) negotiations for 2020 medical drug plans normally finalized in October... MONUMENTAL POSITIVE
3. This will allow pharmacies to increase inventories ( standard of care )to fill subscriptions quicker..... POSITIVE
4. PRIORITY REVIEW means that the FDA understands the unmet need for patient care in the cardiovascular field.....and not about harming Amarin.... STATINS controlled for the last 25 years and that is going to change ... RWE will reflect and support future sales.... POSITIVE
5. A leg up on all other studies ongoing, which will establish Vascepa as the prime drug for physicians right now to prescribe... POSITIVE
BO or GIA ... one direction will come ... will benefit shareholders
Market Data 
Markets 
AI
